Business Context and Reporting Period
This Form 8-K Current Report was filed by cbdMD, Inc. on May 16, 2025. The filing addresses Item 8.01 (Other Events) regarding the Board of Directors' approval of director compensation for the term beginning April 11, 2025.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on non-cash equity grants and cash fee structures for directors.
- Equity Grant: 1,572 Restricted Stock Units (RSUs) issued to each independent and non-management employee director.
- Valuation Basis: RSU value is based on the closing price of common stock (Symbol: YCBD) on NYSE American on May 16, 2025.
- Vesting Schedule: Quarterly vesting on June 30, September 30, and December 31, 2025, and March 31, 2026.
Material Changes and Compensation Structure
The Board approved the following annual cash fee structure for independent directors:
- Base Retainer: $35,000 per year (payable monthly).
- Committee Chair Fees:
- Chairman of the Board: Additional $26,500.
- Chairman of the Audit Committee: Additional $17,000.
- Chairman of the Compensation, Corporate Governance and Nominating Committee: Additional $7,000.
- Committee Member Fees:
- Audit Committee members (excluding chair): Additional $8,500.
- Compensation, Corporate Governance and Nominating Committee members (excluding chair): Additional $4,000.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of risks and contingencies. The only unusual item noted is the specific timing of the equity grant vesting schedule extending into 2026.
Investor Verification Checklist
- Verify the closing price of cbdMD, Inc. (YCBD) on May 16, 2025, to calculate the total fair value of the RSU grants.
- Confirm the number of independent and non-management employee directors to estimate total equity dilution.
- Review the Company's 2015 and 2021 Equity Compensation Plans to ensure sufficient shares remain available for these grants.
- Monitor future filings for the actual issuance of shares upon vesting dates (June 2025 through March 2026).